Recent

% | $
Quotes you view appear here for quick access.

công ty Genomic Health Message Board

  • stupid_hobo73 stupid_hobo73 Feb 10, 2011 1:45 PM Flag

    S&P

    02/09/11 12:53 pm ET ... S&P LOWERS OPINION
    ON SHARES OF GENOMIC HEALTH TO HOLD
    FROM BUY (GHDX 22.1***): Q4 EPS of $0.06, vs.
    a loss of $0.01, is $0.02 ahead of our est. Sales
    rose 19% on solid rise in Oncotype DX breast
    cancer test with robust int'l sales, and limited
    sales of recently introduced Oncotype DX colon
    cancer test.We think GHDX is making good
    progress for reimbursement. GHDX guides '11
    sales of $200-$210M (12-18% growth) and EPS
    of $0.10-$0.17 as profit will be limited by significant
    investment in int'l expansion and product
    development, including next-generation sequencing.
    We are lowering our '11 EPS est
    $0.27 to $0.17 and our target price $4 to $24 on
    revised DCF.

 
GHDX
27.11-0.23(-0.84%)Jul 2 4:00 PMEDT